Home LiteratureArticle Details
PMID: 18519766 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK

Abstract

Defects in the antigen processing machinery (APM) may provide tumor cells with a mechanism to escape immune recognition. The purpose of this study is to determine the clinical significance of APM component down-regulation and tumor-infiltrating T cells in ovarian carcinoma. After institutional review board approval, tumor samples from 150 patients with invasive epithelial ovarian cancers were examined for TAP1, TAP2, tapasin, HLA class I heavy chain (HLA-HC), beta 2 microglobulin, and T-cell (CD3+ and CD8+) tumor infiltration using immunohistochemistry. The majority of tumors had either heterogeneous or positive expression of TAP1, TAP2, HLA-HC, and beta 2 microglobulin (66.7%, 73.3%, 70.7%, and 63.3%, respectively), except tapasin for which 58% of the tumors lacked expression. Furthermore, 67% and 88% of the lesions possessed intratumoral and peritumoral CD3+ or CD8+ cells, respectively. The majority of APM component expression examined was significantly associated with both intratumoral and peritumoral T-cell infiltration (P < 0.05). The expression of APM components and the presence of intratumoral T-cell infiltrates were significantly associated with improved survival (all P < or = 0.01); however, peritumoral T-cell infiltrates did not significantly affect survival (P = 0.33). APM component down-regulation (P < 0.001), lack of intratumoral T-cell infiltrates (P = 0.03), and suboptimal cytoreduction (P < 0.001) were independent prognostic markers for death from ovarian carcinoma. The negative effect of APM component down-regulation by itself and in combination with absent intratumoral T-cell infiltration on the survival of patients with ovarian carcinoma implies a role for immune escape in addition to immunosurveillance in the clinical course of disease.

MeSH Terms
ATP Binding Cassette Transporter, Subfamily B, Member 2 ATP Binding Cassette Transporter, Subfamily B, Member 3 ATP-Binding Cassette Transporters/metabolism Adult Aged Aged, 80 and over Antigen Presentation/physiology Female Histocompatibility Antigens Class I/metabolism Humans Immunohistochemistry Kaplan-Meier Estimate Lymphocytes, Tumor-Infiltrating/immunology Membrane Transport Proteins/metabolism Middle Aged Ovarian Neoplasms/immunology,metabolism,mortality Prognosis T-Lymphocytes/immunology Tumor Escape/immunology beta 2-Microglobulin/metabolism
Chemicals
ATP Binding Cassette Transporter, Subfamily B, Member 2 ATP Binding Cassette Transporter, Subfamily B, Member 3 ATP-Binding Cassette Transporters Histocompatibility Antigens Class I Membrane Transport Proteins TAP1 protein, human beta 2-Microglobulin tapasin TAP2 protein, human
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Han Liz Y
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, CPB6.3244, Unit 1362, Houston, TX 77030, USA.
Fletcher Mavis S
Urbauer Diana L
Mueller Peter
Landen Charles N
Kamat Aparna A
Lin Yvonne G
Merritt William M
Spannuth Whitney A
Deavers Michael T
De Geest Koen
Gershenson David M
Lutgendorf Susan K
Ferrone Soldano
Sood Anil K
References (36)
36 references, click to expand
  1. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
    Nat Rev Cancer. 2003 Jul;3(7):502-16 PMID: 12835670
  2. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.
    J Immunol Methods. 2005 Apr;299(1-2):139-51 PMID: 15896802
  3. HLA class I antigen loss, tumor immune escape and immune selection.
    Vaccine. 2002 Dec 19;20 Suppl 4:A40-5 PMID: 12477427
  4. Cancer vaccines: preclinical studies and novel strategies.
    Adv Cancer Res. 2006;95:115-45 PMID: 16860657
  5. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
    Mol Med Today. 1999 Apr;5(4):178-86 PMID: 10203751
  6. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining.
    Tissue Antigens. 2003 Nov;62(5):385-93 PMID: 14617045
  7. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
    Clin Cancer Res. 2005 Apr 1;11(7):2552-60 PMID: 15814633
  8. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?
    Curr Opin Immunol. 2004 Oct;16(5):644-50 PMID: 15342012
  9. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
    Clin Cancer Res. 2002 Oct;8(10):3193-7 PMID: 12374688
  10. Tumour escape: antitumour effectors too much of a good thing?
    Cancer Immunol Immunother. 2004 Mar;53(3):262-74 PMID: 14685780
  11. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
    Adv Immunol. 2000;74:181-273 PMID: 10605607
  12. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.
    J Immunol. 2006 Mar 15;176(6):3402-9 PMID: 16517708
  13. The structure of the T cell antigen receptor.
    Annu Rev Immunol. 1996;14:563-90 PMID: 8717525
  14. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
    Clin Cancer Res. 2005 Dec 1;11(23):8304-11 PMID: 16322289
  15. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide.
    J Immunol. 2003 Aug 15;171(4):1918-26 PMID: 12902494
  16. 12th International Histocompatibility Conference. Genetic diversity of HLA: functional and medical implications. Paris, France, June 9-12, 1996. Abstracts.
    Hum Immunol. 1996 Apr 15-May;47(1-2):1-184 PMID: 8909580
  17. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
    Clin Cancer Res. 2003 May;9(5):1721-7 PMID: 12738726
  18. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
    J Immunol. 1999 Oct 15;163(8):4224-31 PMID: 10510359
  19. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.
    Cancer Res. 2006 Sep 15;66(18):9281-9 PMID: 16982773
  20. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma.
    Int J Cancer. 1997 Oct 21;74(5):492-501 PMID: 9355970
  21. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  22. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines.
    J Immunol. 1983 May;130(5):2471-8 PMID: 6187860
  23. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications.
    Oncogene. 2005 Jul 7;24(29):4634-44 PMID: 15897905
  24. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.
    Int J Cancer. 2004 Mar 20;109(2):265-73 PMID: 14750179
  25. Cancer immunotherapy: a treatment for the masses.
    Science. 2004 Jul 9;305(5681):200-5 PMID: 15247469
  26. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
    Cancer Immunol Immunother. 2006 Aug;55(8):891-9 PMID: 16187081
  27. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.
    Clin Cancer Res. 2005 Jan 1;11(1):67-72 PMID: 15671529
  28. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
  29. Immunotherapy: bewitched, bothered, and bewildered no more.
    Science. 2004 Jul 9;305(5681):197-200 PMID: 15247468
  30. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
    Cancer Res. 1998 Aug 15;58(16):3491-4 PMID: 9721846
  31. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.
    J Immunol. 1986 Oct 1;137(7):2299-306 PMID: 3760563
  32. Molecular interactions between extracellular components of the T-cell receptor signaling complex.
    Immunol Rev. 1999 Dec;172:73-85 PMID: 10631938
  33. Mechanisms of MHC class I--restricted antigen processing.
    Annu Rev Immunol. 1998;16:323-58 PMID: 9597133
  34. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
    Am J Pathol. 1999 Mar;154(3):745-54 PMID: 10079252
  35. Tumors as elusive targets of T-cell-based active immunotherapy.
    Trends Immunol. 2003 Jun;24(6):335-42 PMID: 12810110
  36. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
    Cancer Res. 2001 Jul 1;61(13):5132-6 PMID: 11431351
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1078-0432
Published
2008-06-01
Pages
3372-9
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC3426216
Subset
IM
Grants
NCI NIH HHS · CA109298 · United States
NCI NIH HHS · 2P50CA083639-06A1 · United States
NCI NIH HHS · R01 CA138188 · United States
NCI NIH HHS · R01 CA109298 · United States
NCI NIH HHS · R01 CA110793 · United States
NCI NIH HHS · R01 CA110249 · United States
NCI NIH HHS · CA110793 · United States
NCI NIH HHS · P01 CA109688 · United States
NCI NIH HHS · P50 CA083639 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com